Drugs / DFP-13318
DFP-13318
also known as
PLX038 · Peg 7-ethyl-10-hydroxycamptothecin · Peg sn38 dfp-13318 · PL-0264 · PLX-0264 · Ultra-long-acting-peg-sn-38
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 12 trials | ||||||
| Phase 1 | NCT06337630 | Jan → Nov 2025 | cancer | Institut Curie | Terminated | No outcome recorded |
| Phase 1 | NCT02646852 | Mar 2016 → Feb 2023 | cancer | ProLynx LLC | Completed | No outcome recorded |
| Phase 1/22 trials | ||||||
| Phase 1/2 | NCT06161519 | Jan 2024 → Nov 2028 expected | ependymoma, glioblastoma, medulloblastoma | National Cancer Institute (NCI) | Recruiting | No outcome recorded |
| Phase 1/2 | NCT04209595 | Apr 2020 → Aug 2021 | small cell lung carcinoma | National Cancer Institute (NCI) | Completed | No outcome recorded |
| Phase 22 trials | ||||||
| Phase 2 | NCT06162351 | Apr 2024 → May 2025 | breast cancer | Institut Curie | Terminated | No outcome recorded |
| Phase 2 | NCT05465941 | Sep 2022 → Dec 2025 overdue | fallopian tube carcinoma, ovarian carcinoma, primary peritoneal carcinoma | Mayo Clinic | Active not recruiting | No outcome recorded |
Evidence & citations 10 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DFP-13318 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095369 ↗ |
| Known as | Peg 7-ethyl-10-hydroxycamptothecin | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095369 ↗ |
| Known as | Peg sn38 dfp-13318 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095369 ↗ |
| Known as | PL-0264 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095369 ↗ |
| Known as | PLX-0264 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095369 ↗ |
| Known as | PLX038 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05465941 ↗ |
| Known as | Ultra-long-acting-peg-sn-38 | ChEMBL registry synonym — accepted as the source's own label CHEMBL5095369 ↗ |
| Action | Inhibit | “PLX038 (Topo1 Inhibitor)” NCT06337630 ↗ |
| Modality | Other / unclassified | “PLX038 is a PEGylated conjugate of SN38 with improved properties including increased solubility, higher exposure and longer half-life.” NCT04209595 ↗ |
| Route | Intravenous | “PLX038 intravenous infusion” NCT02646852 ↗ |